Progesterone Receptor Mouse anti-Human, Biotin, Clone: KMC912, eBioscience™

Mouse Monoclonal Antibody

Overview
Brand: Affymetrix eBioscience

Manufacturer Part Number: 13-9764-80

25UG Anti-Human Progesterone Receptor Biotin

Code: NEW

Additional Details:
Additional Details: Weight: 0.09500kg



Disclaimers: For Research Use Only.

Product Code. 15587376

Quantity Price
1 £ 92.2 / 25µg
Estimated Shipment date
from Supplier 09-12-2016
Add to basket


Description and Specification

Specification

Antigen Progesterone Receptor
Applications Immunocytochemistry
Applications Immunohistochemistry (Formalin/Paraffin)
Applications Microscopy
Clone KMC912
Concentration 0.5mg/mL
Conjugate Biotin
Format Conjugated
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Gene Alias PR, PgR
Host Species Mouse
Isotype IgG1
Quantity 25μg
Regulatory Status RUO
Species Reactivity Human
Storage Requirements Store at 2-8°C. Do not freeze.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal

This KMC912 monoclonal antibody reacts with human progesterone receptor (PgR, PR), a member of a superfamily of nuclear receptors that are ligand-dependent transcriptional regulators. The human PgR exists in alpha and beta forms, 94kDa and 120kDa respectively. In most human cells, the alpha and beta forms are expressed at similar levels and predominately form heterodimers. Progestin binding to PgR causes a conformational change, allowing dissociation of bound chaperone proteins and subsequent dimerization with either PgRa or PgRb. Following activation, dimerized PgR can directly bind to DNA through progestin response elements (PRE) leading to chromatin remodeling and subsequent downregulation or transcription of the target gene.The PgR plays a key role in controlling gene expression in breast, uterine, brain, and cardiovascular tissue during development. The presence of the PgR in breast tissue is indicative of improved survival and a better response to endocrine therapy. In breast and endometrial cancer progression, a predominance of either the alpha or beta form occurs, suggesting disregulation in the PgRa:PgRb ratio is an early event in cancer. In cases of ductal carcinoma in situ and invasive ductal carcinoma, there is predominance of the alpha form while in uterine cancer a loss of either form is common.